New Medications for Dry Eye and Presbyopia

Topical miotics are approved for use in all adults with presbyopia, including post-LASIK patients and pseudophakes, and acoltremon is a treatment option for multiple dry eye subtypes, either as primary therapy or adjunctive treatment.

By
Sarah Fackler, managing editor, Optometric Management
January 1, 2026
4 min

Optometric Management

Overview

Expand on the significance of improvements in near visual acuity and dry eye symptoms for each medication.

Background

The management of dry eye disease and presbyopia is crucial due to their high prevalence, particularly among aging populations. New pharmacologic therapies provide innovative solutions that can enhance patient quality of life. Understanding these options is essential for healthcare professionals to optimize treatment strategies.

Data Highlights

{'aceclidine': {'dosing': '2 drops per eye once daily, separated by 2 minutes.'}}

Key Findings

{'adverse_events': 'Include specific percentages for headache and instillation site pain.'}

Clinical Implications

Highlight the need for monitoring specific adverse events like blurred vision and caution with night driving.

Conclusion

The introduction of new topical therapies for dry eye and presbyopia represents a significant advancement in ophthalmic care. These options provide healthcare professionals with effective tools to enhance patient management and improve visual function.